17.05.2019

Neophore's SAB member publishes article on JCO Precision Oncology

Dr. Luis Diaz, Neophore’s Scientific Advisory Member and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital has recently published the paper entitled "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High”. The study underpins Neophore’s therapeutic concept by describing how patients with loss of protein expression due to cancer obtain clinical benefit from immune checkpoint inhibitors. See full article here: bit.ly/2VveVTB

More news

08.07.2019

NeoPhore appoints Dr Matthew Baker as VP Immunology

08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker a…

20.03.2019

NeoPhore appoints Dr John Haurum as Non-Executive Director

Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…

27.04.2018

NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…